APA (7th ed.) Citation

Jondreville, L., D’Aveni, M., Labussière-Wallet, H., Le Bourgeois, A., Villate, A., Berceanu, A., . . . Nguyen, S. (2022). Pre-exposure prophylaxis with tixagevimab/cilgavimab (AZD7442) prevents severe SARS-CoV-2 infection in recipients of allogeneic hematopoietic stem cell transplantation during the Omicron wave: A multicentric retrospective study of SFGM-TC. Journal of hematology and oncology, 15(1), 169-4. https://doi.org/10.1186/s13045-022-01387-0

Chicago Style (17th ed.) Citation

Jondreville, Ludovic, et al. "Pre-exposure Prophylaxis with Tixagevimab/cilgavimab (AZD7442) Prevents Severe SARS-CoV-2 Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation During the Omicron Wave: A Multicentric Retrospective Study of SFGM-TC." Journal of Hematology and Oncology 15, no. 1 (2022): 169-4. https://doi.org/10.1186/s13045-022-01387-0.

MLA (9th ed.) Citation

Jondreville, Ludovic, et al. "Pre-exposure Prophylaxis with Tixagevimab/cilgavimab (AZD7442) Prevents Severe SARS-CoV-2 Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation During the Omicron Wave: A Multicentric Retrospective Study of SFGM-TC." Journal of Hematology and Oncology, vol. 15, no. 1, 2022, pp. 169-4, https://doi.org/10.1186/s13045-022-01387-0.